AIQ’s TRAQinform IQ software quantifies and classifies lesion-specific treatment response and organ-specific toxicity from longitudinal imaging scans. It can deliver an early prediction of optimal/suboptimal responders to therapies allowing for optimal patient selection and more efficient go/no-go clinical decisions. It also provides concordance between multiple imaging modalities and radiotracers. AIQ has the ONLY technology that can quantify and characterize treatment response and toxicity risk for each individual lesion and organ system automatically. The technology is FDA-cleared.